期刊
AMERICAN JOURNAL OF PATHOLOGY
卷 190, 期 10, 页码 2080-2094出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2020.06.006
关键词
-
类别
资金
- NIH [4R01DK095498, 5F30DK107129]
- Pittsburgh Liver Research Center for the Biospecimen Repository and Processing Core grant [P30DK120531]
Platelet-derived growth factor receptor (PDGFR)-alpha plays roles in cell survival, proliferation, and differentiation; however, its function in chronic liver injury sequelae, such as fibrosis, is unknown. Hepatic stellate cells (HSCs), the primary mediators of fibrosis, undergo activation, which entails differentiation to myofibroblasts, proliferation, migration, and collagen deposition, partially in response to PDGFs. To examine the role of PDGFR-alpha in HSCs, Lrat-Cre recombinase and Pdgfra-floxed mice were bred to generate Lrat-Cre Pdgfra-/- (knockout) animals, which were subjected to chronic liver injury through carbon tetrachloride treatment, bile duct ligation, and 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Although no major difference was observed after other types of liver injury, PDGFR-alpha loss in HSCs led to a significant albeit transient reduction in fibrosis after carbon tetrachloride injury, associated with increased HSC death and reduced migration. There was continued alleviation of hepatocellular injury in knockout mice despite ongoing carbon tetrachloride insult, associated with increased numbers of CD68 and F480 macrophages and increased clearance of damaged hepatocytes. Altogether our findings support a profibrotic role of PDGFR-alpha in HSCs during chronic liver injury in vivo via regulation of HSC survival and migration and affect the immune microenvironment, especially macrophages in clearing dying hepatocytes. Thus, our study provides a preclinical foundation for the future testing of therapeutic PDGFR-a inhibition in hepatic fibrosis, especially in combination with other therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据